GlassScriptPhysician profile
Jaime J Sanchez
NPI 1154390441
$14,645.18
in general payments reported to CMS, 2019-2025
40 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,820 · 2020: $780 · 2021: $3,313 · 2022: $1,843 · 2023: $2,220 · 2024: $2,572 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,872 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,872.04 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,036.77 | 2019-2025 | Aveir, Jot Dx, Mitraclip |
| Biotronik INC. | $3,957.43 | 2019-2023 | Acticor 7 Vr-T Dx, Biomonitor |
| Novartis Pharmaceuticals Corporation | $831.56 | 2019-2025 | |
| Boston Scientific Corporation | $659.17 | 2019-2024 | Watchman Flx |
| Pfizer INC. | $456.36 | 2019-2025 | |
| Amgen INC. | $397.70 | 2019-2025 | Repatha |
| Actelion Pharmaceuticals US, INC. | $379.98 | 2023-2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.18 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $371.62 | 2019-2025 | Eliquis, Camzyos |
| Lexicon Pharmaceuticals, INC. | $311.48 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $266.08 | 2021-2025 | Lokelma |
| Heartflow, INC. | $245.34 | 2023-2024 | Ffrct |
| Janssen Pharmaceuticals, INC | $231.01 | 2019-2023 | Xarelto |
| Scpharmaceuticals INC. | $200.48 | 2024-2025 | |
| Catheter Precision, INC. Fka Ra Medical Systems, INC. | $175.19 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.